Pediatric Dermatology News

Scabies and impetigo prevalence was reduced significantly with mass administration of ivermectin or permethrin in small Indian communities, according to a study.

The CMS finalized cuts to the 2025 physician fee schedule for the fifth year in a row, prompting an urgent call-to-action from the American Academy of Dermatology. HHS, through the CMS, announced the finalization of the 2025 Medicare Physician Fee Schedule.

Roflumilast cream 0.15% showed high efficacy rates among patients aged 6 years and older with mild to moderate atopic dermatitis, according to a study.

The FDA’s inaction approving sunscreen ingredients as well as studies about endocrine-disrupting chemicals in personal care products and Ozempic’s impact on hidradenitis suppurativa led Healio Dermatology’s most-read articles in September.

A previously healthy, 14-year-old girl is admitted to the hospital after complaints of painful swelling of her lower lip, with periodic spotty, blood-tinged drainage from several discrete areas with overlying dark scabs.

Adbry 300 mg/2 mL single-dose autoinjector is now available for the treatment of adults with moderate to severe atopic dermatitis in the U.S., LEO Pharma announced in a press release.

Celebrity news and nutrition stories led Healio Dermatology’s most-read articles in August.

Eli Lilly and Company announced it received FDA approval for Ebglyss for the treatment of moderate-to-severe atopic dermatitis that is not well controlled with topical prescription therapies, according to a company press release.

The use of personal care products was associated with endocrine-disrupting chemicals called phthalates in children aged as young as 4 years, according to a study.